CD97/ADGRE5 attenuates the induction of adaptive type 2 immune responses in allergic asthma.

CD97/ADGRE5 suppresses early immune activation, reducing airway inflammation in allergic asthma, with deficiency leading to a 2-fold increase in disease severity.

• Why it matters: Understanding immune regulation in asthma is crucial for developing targeted therapies, as uncontrolled type 2 responses cause airway hyperreactivity and inflammation.
• What they did: Researchers used mouse models lacking CD97 and applied antibody treatments to examine immune responses, alongside analyzing human airway samples, focusing on dendritic cell activity and cytokine production.
• The result: Loss of CD97 heightened dendritic cell activation and type 2 cytokine secretion, worsening asthma symptoms, suggesting CD97 as a promising target for controlling allergic airway inflammation.